Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 18/20 | 0.54 |
| ▸ | PLG | P00747 | 14/20 | 0.54 |
| ▸ | F10 | P00742 | 7/20 | 0.54 |
| ▸ | ST14 | Q9Y5Y6 | 7/20 | 0.54 |
| ▸ | F2 | P00734 | 6/20 | 0.54 |
| ▸ | PLAT | P00750 | 4/20 | 0.54 |
| ▸ | HPN | P05981 | 3/20 | 0.54 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.54 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.54 |
| ▸ | HGFAC | Q04756 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| N-(Ethoxycarbonyl)Piperazine SCHEMBL2874625 | 0.81 | PLAU (0.80) | PLAUPLGF10ST14F2 | |
| N-(Ethoxycarbonyl)Piperazine SCHEMBL4606324 | 0.80 | PLAU (0.80) | PLAUPLGF10ST14F2 | |
| N-(Ethoxycarbonyl)Piperazine SCHEMBL1809303 | 0.80 | PLAU (0.67) | PLAUPLGF10ST14F2 | |
| N-(Ethoxycarbonyl)Piperazine SCHEMBL2880394 | 0.79 | PLAU (0.63) | PLAUPLGF10ST14F2 | |
| N-(Ethoxycarbonyl)Piperazine SCHEMBL2875164 | 0.79 | PLAU (0.65) | PLAUPLGF10ST14F2 | |
| N-(Ethoxycarbonyl)Piperazine SCHEMBL3660147 | 0.78 | PLAU (0.58) | PLAUPLGF10ST14F2 | |
| N-(Ethoxycarbonyl)Piperazine SCHEMBL2875579 | 0.78 | PLAU (0.61) | PLAUPLGF10ST14F2 | |
| N-(Ethoxycarbonyl)Piperazine SCHEMBL3257068 | 0.78 | PLAU (0.52) | PLAUPLGF10ST14F2 | |
| N-(Ethoxycarbonyl)Piperazine SCHEMBL3664982 | 0.77 | PLAU (0.49) | PLAUPLGF10ST14F2 | |
| N-(Ethoxycarbonyl)Piperazine SCHEMBL3258134 | 0.77 | PLAU (0.51) | PLAUPLGF10ST14F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7659396-B2 | Method for the production of phenylalanine derivatives | WILEX AG (DE) | 2010-02-09 | — | — | US | claimed |
| US-20090005562-A1 | Method for the Production of Phenylalanine Derivatives | WILEX AG (DE) | 2009-01-01 | — | — | US | claimed |
| US-20050245757-A1 | Method for the production of phenylalanine derivatives | WILEX AG (DE) | 2005-11-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005562-A1 | Method for the Production of Phenylalanine Derivatives | PAH, NPEPPS, DNPEP | PLAU 1008/4885PLG 1705/4885F10 4029/4885 |
| US-20050245757-A1 | Method for the production of phenylalanine derivatives | PAH, NPEPPS, DNPEP | PLAU 1008/4885PLG 1705/4885F10 4029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.